Search Results 361-370 of 16233 for SC

  1. Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol - Mayo Clinic

    ... (SC) inclisiran injection(s). The study will be a multicenter study in the United States. Participation eligibility. Participant eligibility includes age ...

  2. Publications - Adam L. Holtzman, M.D. - Mayo Clinic

    Olson B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, Graves J, Vallecillo T, Ma DJ, Neben-Wittich MA, Lester SC, Gamez M, Holtzmann A, Mohammadi H, Garcia J ...

  3. Hypereosinophilic Syndrome Clinical Trials - Mayo Clinic Research

    ... (SC) for an additional 20 Weeks after completing the 32 Week study assessments post-randomization, while they continue with their background HES therapy per ...

  4. Gastroenterology and Hepatology - Clinical trials

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  5. Publications - Chris M. Adams, M.D., Ph.D. - Mayo Clinic

    ... SC, Bround MJ, Sargent MA, Adams CM, Molkentin JD. Thbs1 regulates skeletal muscle mass in a TGFbeta-Smad2/3-ATF4-dependent manner. Cell Rep. 2024 May 28 ...

  6. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

    ... SC dose at Week 0, followed by one 40 mg SC dose at Week 2, in countries where this dosing regimen is approved]);; At least one 4-week induction regimen ...

  7. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

    About this study. The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks ...

  8. Morphine (injection route) - Side effects & uses - Mayo Clinic

    Morphine injection is used to treat pain severe enough to require opioid treatment and when other pain medicines did not work well enough or cannot be tolerated ...

  9. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

    ... (SC) for an additional 20 Weeks after completing the 32 Week study assessments post-randomization, while they continue with their background HES therapy per ...

  10. Shaheen S. Kurani - Training and Education - Center for Clinical and Translational Science (CCaTS)

    Anthropology and Human Biology, Emory University; Sc.M., Public Health and Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public ...